Department of Pediatrics Gynecology and Obstetrics, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.
National Research Council of Italy (CNR), Institute of Translational Pharmacology IFT, Via Fosso del Cavaliere 100, 00133, Rome, Italy.
Ital J Pediatr. 2021 Mar 8;47(1):54. doi: 10.1186/s13052-021-01007-6.
Transcobalamin deficiency is a rare autosomal recessive inborn error of cobalamin transport (prevalence: < 1/1000000) which clinically manifests in early infancy.
We describe the case of a 31 years old woman who at the age of 30 days presented with the classical clinical and laboratory signs of an inborn error of vitamin B metabolism. Family history revealed a sister who died at the age of 3 months with a similar clinical syndrome and with pancytopenia. She was started on empirical intramuscular (IM) cobalamin supplements (injections of hydroxocobalamin 1 mg/day for 1 week and then 1 mg twice a week) and several transfusions of washed and concentrated red blood cells. With these treatments a clear improvement in symptoms was observed, with the disappearance of vomiting, diarrhea and normalization of the full blood count. At 8 years of age injections were stopped for about two and a half months causing the appearance of pancytopenia. IM hydroxocobalamin was then restarted sine die. The definitive diagnosis could only be established at 29 years of age when a genetic evaluation revealed the homozygous c.1115_1116delCA mutation of TCN2 gene (p.Q373GfsX38). Currently she is healthy and she is taking 1 mg of IM hydroxocobalamin once a week.
Our case report highlights that early detection of TC deficiency and early initiation of aggressive IM treatment is likely associated with disease control and an overall favorable outcome.
转钴胺素 2 缺乏症是一种罕见的常染色体隐性遗传性钴胺素转运缺陷(患病率:<1/1000000),临床上表现为婴儿早期发病。
我们描述了一名 31 岁女性的病例,其在 30 天大时出现了维生素 B 代谢先天错误的典型临床和实验室征象。家族史显示其姐姐在 3 个月大时也出现了类似的临床综合征和全血细胞减少症,并因此死亡。她接受了经验性肌内(IM)钴胺素补充治疗(羟钴胺素 1mg/天,共 1 周,然后每周 2 次,每次 1mg)和多次洗涤浓缩红细胞输注。这些治疗措施明显改善了症状,呕吐、腹泻消失,全血细胞计数恢复正常。8 岁时,因停止治疗约两个半月而出现全血细胞减少症,随后再次开始 IM 羟钴胺素治疗,且无停药计划。只有在 29 岁进行基因评估时发现 TCN2 基因的纯合 c.1115_1116delCA 突变(p.Q373GfsX38),才能明确诊断。目前,她身体健康,每周接受 1mg IM 羟钴胺素治疗。
我们的病例报告强调,早期发现 TC 缺乏症并尽早开始积极的 IM 治疗,可能与疾病控制和整体良好预后相关。